@article{dd8743a606be453c86cb9b96267ea84f,
title = "Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer",
abstract = "The companion diagnostic test for checkpoint inhibitor immune therapy is an immunohistochemical test for PD-L1. The test has been shown to be reproducible for expression in tumor cells, but not in immune cells. Immune cells were used in the IMpassion130 trial which showed PD-L1 expression was associated with a better outcome. Two large studies have been done assessing immune cell PD-L1 expression in lung cancer. Here, we reanalyze one of those studies, to show that, even with an easier scoring method, there is still only poor agreement between assays and pathologist for immune cell PD-L1 expression.",
keywords = "Atezolizumab, Immunohistochemistry, Non-small cell lung cancer, PD-L1, Triple-negative breast cancer",
author = "Rimm, {David L.} and Gang Han and Taube, {Janis M.} and Yi, {Eunhee S.} and Bridge, {Julia A.} and Flieder, {Douglas B.} and Robert Homer and Roden, {Anja C.} and Hirsch, {Fred R.} and Wistuba, {Ignacio I.} and Lajos Pusztai",
note = "Funding Information: This work was supported in part by funding the Yale SPORE in Lung Cancer (P50CA196530) and funds from the Yale Comprehensive Cancer Center (P30CA016359). Funding Information: This study was funded by Bristol-Myers Squibb in collaboration with the National Comprehensive Cancer Network Oncology Research Program and by the Breast Cancer Research Foundation. Funding Information: Dr. Rimm reported serving as a consultant for AstraZeneca, Agendia, Bethyl Labs, Biocept, Bristol-Myers Squibb, Cell Signaling Technology, ClearSight, Genoptix/Novartis, Merck, OptraScan, Perkin Elmer, and Ultivue and receiving research grant support from Cepheid, Genoptix, Gilead Sciences, Pierre Fabre, and Perkin Elmer. Dr. Taube reported serving as a consultant for Bristol-Myers Squibb, AstraZeneca, and Merck and receiving research funding from Bristol-Myers Squibb. Dr. Bridge reported serving as a consultant for Cepheid Inc and National Comprehensive Cancer Network–Peregrine. Dr. Anders reported serving on the advisory board of Adaptive Biotechnologies and receiving research support from Bristol-Myers Squibb, Five Prime Diagnostics, National Institutes of Health, Stand Up 2 Cancer, and Fibrolamellar Cancer Foundation. Dr. Hirsch reported serving on the advisory boards of Genentech/Roche, Bristol-Myers Squibb, Merck, AstraZeneca, Novartis, Pfizer, Ventana, and HTG Molecular Diagnostics Inc. Dr. Wistuba reported receiving honoraria from Genentech/Roche, Bristol-Myers Squibb, Boehringer Ingelheim, AstraZeneca, Pfizer, Ariad, HTG Molecular Diagnostics Inc, and Asuragen and receiving research grants from Genentech/Roche, Bristol-Myers Squibb, HTG Molecular Diagnostics Inc, and Asuragen. Drs. Batenchuk and Burns were employed by Bristol-Myers Squibb. Dr Pusztai has received consulting fees and honoraria from Astra Zeneca, Merck, Novartis, Genentech, Eisai, Pieris, Immunomedics, Seattle Genetics, Almac and Syndax. Publisher Copyright: {\textcopyright} 2019 The Author(s).",
year = "2019",
month = jun,
day = "13",
doi = "10.1186/s13058-019-1156-6",
language = "English (US)",
volume = "21",
journal = "Breast Cancer Research",
issn = "1465-5411",
publisher = "BioMed Central Ltd.",
number = "1",
}